STM publisher Elsevier, Netherlands, has announced that PharmaPendium, a source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.
The addition of the module to PharmaPendium's existing content is projected to give researchers a greater understanding and visibility of Drug-Drug Interactions (DDI) and their potential adverse reactions during the critical stages of drug discovery and development.
The new module will reportedly benefit researchers including toxicologists, pharmacokinetics researchers and departments, safety pharmacologists and clinical pharmacologists, who demand the highest quality data on preclinical and clinical metabolising enzymes and transporters. These researchers often struggle to find comparative data to understand how changes in the activity of metabolising enzymes and transporters affect the safety and efficacy of drugs. Currently, available information on DDIs is seen to be hard to collate and analyse and is not always normalised for comparison, making data analysis not only labour and cost intensive, but also open to critical error.
PharmaPendium's Metabolising Enzymes and Transporters Module is said to allow for rapid, full text-search of literature from sources including approval documents from the Food and Drug Administration (FDA) and European Medicines Agency (EMA). It extracts both in vivo and in vitrohuman and animal experimental data on metabolising enzymes and transporters contained in preclinical and clinical studies, and applies it to the context of researchers' experiments, facilitating efficient and diligent drug development.
PharmaPendium is part of Elsevier's Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow, including Reaxys, Reaxys Medicinal Chemistry, ScienceDirect, Scopus, TargetInsights, Pathway Studio and Embase.
PharmaPendium Metabolising Enzymes and Transporters Module is available immediately. For more information go to www.elsevier.com/pharmapendium.
